Pillar Biosciences
Focus: Pillar Biosciences develops targeted next-generation sequencing (NGS)-based assays and software, primarily serving the ophthalmology market. The company is a specialized biotech player focused on diagnostic and research tools rather than therapeutic development.
Profile data last refreshed 23h ago · AI intelligence enriched 2w ago
Open Jobs
1
Should You Work at Pillar Biosciences?
AI assessmentBest suited for diagnostics specialists or early-stage biotech risk-takers seeking equity upside; avoid if seeking stable, revenue-generating company environment.
Why Work Here
- Niche expertise in NGS assays and companion diagnostics positions you in a high-growth molecular diagnostics market
- 100% H1B approval rate (7/7 in 2023) signals strong visa sponsorship and commitment to top talent
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pillar Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.